Crescent Biopharma develops cancer treatments, including antibody and antibody drug conjugate candidates still in clinical trials. CBIO reports earnings on Thu, Nov 5, 2026. Over the past 90 days StreetAlpha recorded 1 whale options trade in CBIO, 100% of them bullish and 0% bearish.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | HC Wainwright & Co. | Reiterated | Buy | |
| Oct 6 | HC Wainwright & Co. | Upgrade | Buy | |
| Aug 27 | Wedbush | Reiterated | Buy |
Whale Options Flow
90DNo whale options trades in CBIO in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CBIO is in one of them and how their past CBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered CBIO in an article yet. Here's the latest on the wider market.
About Crescent Biopharma
Crescent Biopharma is a biotechnology company based in Waltham, Massachusetts, that develops treatments for cancer. Its lead candidate, CR-001, is an antibody designed to bind two proteins, PD-1 and VEGF, that affect how tumors grow and how the immune system responds. The company is also developing antibody drug conjugates, which are designed to deliver a toxin directly to cancer cells. Its candidates are still in clinical trials and are not yet approved for sale.
- Headquarters
- Waltham, MA